Clot life span model analysis of clot growth and fibrinolysis in normal subjects: Role of thrombin activatable fibrinolysis inhibitor

Blood Coagulation and Fibrinolysis

Volumn 19, Issue 4, 2008, Pages 283-287

  Nielsen, Vance G ^a,b  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^b UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

Coagulation; Fibrinolysis; Measurement techniques; Thrombelastography; Thrombin activatable fibrinolysis inhibitor; Tissue type plasminogen activator

Indexed keywords

ENZYME INHIBITOR; KAOLIN; POTATO CARBOXYPEPTIDASE INHIBITOR; THROMBIN ACTIVATABLE FIBRINOLYSIS INHIBITOR; THROMBOPLASTIN; TISSUE PLASMINOGEN ACTIVATOR;

ADULT; ARTICLE; BLOOD CLOTTING; BLOOD CLOTTING TIME; FIBRINOLYSIS; HUMAN; HUMAN EXPERIMENT; KINETICS; LIFESPAN; MODEL; NORMAL HUMAN; PLASMA; PRIORITY JOURNAL; THROMBOELASTOGRAPHY; THROMBUS;

ADULT; BLOOD COAGULATION; FEMALE; FIBRINOLYSIS; HUMANS; MALE; MIDDLE AGED; REFERENCE VALUES; THROMBELASTOGRAPHY;

EID: 43449139439     PISSN: 09575235     EISSN: None     Source Type: Journal    
DOI: 10.1097/MBC.0b013e3282ff76c3     Document Type: Article

References (19)

1. Artang R, Jensen E, Pedersen F, Frandsen NJ. Thrombelastography in healthy volunteers, patients with stable angina and acute chest pain. Thromb Res 2000; 97:499-503.
2. McCrath DJ, Cerboni E, Frumento RJ, Hirsh AL, Bennett-Guerrero E. Thromboelastography maximum amplitude predicts postoperative thrombotic complications including myocardial infarction. Anesth Analg 2005; 100:1576-1583.
3. Bliden KP, DiChiara J, Tantry US, Bassi AK, Chaganti SK, Gurbel PA. Increased risk in patients with high platelet aggregation receiving chronic clopidogrel therapy undergoing percutaneous coronary intervention: is the current antiplatelet therapy adequate? J Am Coll Cardiol 2007;49:657-666.
4. Wettstein P, Haeberli A, Stutz M, Rohner M, Corbetta C, Gabi K, et al. Decreased factor XIII availability for thrombin and early loss of clot firmness in patients with unexplained intraoperative bleeding. Anesth Analg 2004;99:1564-1569.
5. Poston R, Gu J,Manchio J, Lee A, Brown J, Gammie J, et al. Platelet function tests predict bleeding and thrombotic events after off-pump coronary bypass grafting. Eur J Cardiothorac Surg 2005; 27:584-591.
6. Welsby IJ, Jiao K, Ortel TL, Brudney CS, Roche AM, Bennett-Guerrero E, Gan TJ. The kaolin-activated thrombelastograph predicts bleeding after cardiac surgery. J Cardiothorac Vasc Anesth 2006; 20:531-535.
7. Spalding GJ, Hartrumpf M, Sierig T, Oesberg N, Kirschke CG, Albes JM. Cost reduction of perioperative coagulation management in cardiac surgery: value of "bedside" thrombelastography (ROTEM). Eur J Cardiothorac Surg 2007; 31:1052-1057.
8. Ellis TC, Nielsen VG, Marques MB, Kirklin JK. Thrombelastographic measures of clot propagation: a comparison of alpha to maximum rate of thrombus generation. Blood Coagul Fibrinolysis 2007; 18:45-48.
9. Nielsen VG, Cohen BM, Cohen E. Elastic modulus-based thrombelastographic quantification of plasma clot fibrinolysis with progressive plasminogen activation. Blood Coagul Fibrinolysis 2006; 17:75-81.
10. Nielsen VG, Ellis TC. Thrombelastographic quantification of the contributions of thrombin activatable fibrinolysis inhibitor and alpha2-antiplasmin to antifibrinolytic activity in human plasma. Blood Coagul Fibrinolysis 2007; 18:29-33.
11. Nielsen VG, Steenwyk BL, Gurley WQ. Contact activation prolongs clot lysis time in human plasma: role of thrombin activatable fibrinolysis inhibitor and factor XIII. J Heart Lung Transplant 2006; 25:1247-1252.
12. Nielsen VG. Protamine enhances fibrinolysis by decreasing clot strength: role of tissue factor-initiated thrombin generation. Ann Thorac Surg 2006; 81:1720-1727.
13. Nielsen VG. Hemodilution modulates the time of onset and rate of fibrinolysis in human and rabbit plasma. J Heart Lung Transplant 2006; 25:1344-1352.
14. Nielsen VG, Cankovic L, Steenwyk BL. Epsilon aminocaproic acid inhibition of fibrinolysis in vitro: should the "therapeutic" concentration be reconsidered? Blood Coagul Fibrinolysis 2007; 18:35-39.
15. Nielsen VG. Hydroxyethyl starch enhances fibrinolysis in human plasma by diminishing α2-antiplasmin-plasmin interactions. Blood Coagul Fibrinolysis 2007; 18:647-656.
16. Saibeni S, Bottasso B, Spina L, Bajetta M, Danese S, Gasbarrini A, et al. Assessment of thrombin-activatable fibrinolysis inhibitor (TAFI) plasma levels in inflammatory bowel diseases. Am J Gastroenterol 2004; 99:1966-1970.
17. Hataji O, Taguchi O, Gabazza EC, Yuda H, D'Alessandro-Gabazza CN, Fujimoto H, et al. Increased circulating levels of thrombin-activatable fibrinolysis inhibitor in lung cancer patients. Am J Hematol 2004; 76:214-219.
18. Leebeek FWG, Van Goor MPJ, Guimaraes AHC, Brouwers GJ, De Maat MPM, Dippel DWJ, et al. High functional levels of thrombin-activatable fibrinolysis inhibitor are associated with an increased risk of first ischemic stroke. J Thromb Hemost 2005; 3:2211-2218.
19. Mosnier LO, Bouma BN. Regulation of fibrinolysis by thrombin activatable fibrinolysis inhibitor, an unstable carboxypeptidase B that unites the pathways of coagulation and fibrinolysis. Arterioscler Thromb Vasc Biol 2006; 26:2445-2453.